Specific Phobia

Earn CME/CE in your profession:

Continuing Education Activity

Specific phobia is a common anxiety disorder. Patients with specific phobias experience anxiety and panic attacks along with unreasonable fear of exposure or anticipated exposure to a phobic stimulus. The anxiety response goes beyond normal apprehension and leads to avoidance behavior. The intensity of the fear is often disproportionate to the actual danger posed by the phobic stimulus. This activity outlines the current DSM-5-TR diagnostic criteria for specific phobia, shedding light on validated assessment tools and evidence-based treatments, notably focusing on the amalgamation of therapeutic methods for enhanced patient outcomes. Emphasizing interprofessional collaboration, this session underscores the necessity of a holistic approach involving psychiatrists, psychologists, and allied healthcare professionals in managing patients with specific phobia. 

Furthermore, the course discussion highlights the historical evolution of understanding phobias, from ancient observations to Freudian conceptualizations as psychological defense mechanisms and the subsequent influence of behaviorism on the perception of phobic behavior as learned responses. Advancements in neuroscience and the role of the amygdala in fear processing contribute to the contemporary understanding of specific phobias. The evolution of therapeutic approaches, encompassing behavior therapy like systematic desensitization and the prominence of cognitive-behavioral therapy, reflects the ongoing development of interventions grounded in psychological and neurobiological understanding. This activity aims to equip healthcare professionals with updated knowledge and comprehensive strategies to diagnose, assess, and treat specific phobia, recognizing its impact on patients' quality of life and social functioning.


  • Differentiate specific phobia from other anxiety disorders based on DSM-5-TR diagnostic criteria and clinical presentation.

  • Implement validated assessment tools effectively during clinical evaluations for a thorough diagnosis of specific phobia. 

  • Select the most appropriate evidence-based treatment modalities for specific phobia, aligned with patient preferences, comorbidities, and treatment goals.

  • Collaborate with the interprofessional team to enhance clinical outcomes for patients with specific phobia. 


Anxiety describes an uncomfortable emotional state characterized by inner turmoil and dread over anticipated future events. Anxiety is closely related to and overlaps with fear, which is a response to perceived and actual threats. Anxiety often results in nervousness, rumination, pacing, and somatization. Every human experiences anxiety because it is an evolved behavioral response to prepare an individual to detect and deal with threats.[1] Anxiety becomes pathological when it is so overwhelming that there is persistent distress, a decrease in the quality of life, and impairment in regular major life activities.[2]

Anxiety disorders are common psychiatric disorders and are often underrecognized.[3] Untreated anxiety disorders can significantly impair the quality of life, lead to comorbid psychiatric conditions, and interfere with social functioning.[4][5] Individuals with anxiety disorders may experience a poorer quality of life compared to those without anxiety disorders, and the severity of anxiety can impact daily functioning.[6]

Specific phobia is an anxiety disorder characterized by excessive and irrational fear of a particular object, situation, or activity. The anxiety response goes beyond normal apprehension and leads to avoidance behavior. The intensity of the fear is often disproportionate to the actual danger posed by the phobic stimulus. Common examples of specific phobias include fear of heights (acrophobia), fear of spiders (arachnophobia), fear of flying (aviophobia), and fear of needles (trypanophobia). People with specific phobias may experience intense anxiety or panic attacks when exposed to the feared object or situation.[7]

Historically, extreme fears of specific situations or objects have been documented as far back as the ancient Greeks and Romans. In the late 19th and early 20th centuries, Sigmund Freud proposed that phobias were a psychological defense mechanism arising from repressed psychological conflict. These ideas influenced early psychological thought on phobias but were later critiqued and expanded upon.[8] In the early 20th century, behaviorism became a dominant force in psychology—researchers like John B. Watson and B.F. Skinner emphasized observable behaviors and learning through conditioning. Phobias were often seen as learned responses, with specific phobias thought to develop through classical conditioning (associating a neutral stimulus with a negative experience).

The Diagnostic and Statistical Manual of Mental Disorders (DSM) is a key resource for classifying mental health disorders; in its various editions, specific phobias have been included and refined. The DSM-III (1980) marked a significant step in systematically classifying phobias. Advances in neuroscience and research have contributed to a better understanding of the neural mechanisms underlying specific phobias, including insights into the role of the amygdala, a brain region involved in processing fear.[7]

Over time, therapeutic approaches for specific phobias have evolved. Behavior therapy, including systematic desensitization (a type of exposure therapy), has been a key component. Cognitive behavioral therapy has also become a prominent and effective approach, focusing on changing negative thought patterns and behaviors associated with phobias. Today, specific phobias are recognized as a common type of anxiety disorder, and treatment approaches continue to evolve based on ongoing research and a deeper understanding of the psychological and neurobiological factors involved.[9]


The etiology of most psychiatric conditions involves various degrees and types of biological, psychological, and social contributors. Although psychological factors particularly impact the development of anxiety disorders, there are multiple biological components to pathological anxiety. The study of inheritance patterns has revealed a general familial aggregation among major anxiety disorders.[10] Twin studies have demonstrated stronger inheritance patterns for monozygotic twins compared to dizygotic twins, suggesting a genetic component to the development of pathological anxiety.[11] Although the study of anxiety and gene-environment interactions is limited, it is known that epigenetic mechanisms, particularly DNA methylation, contribute to mediating transcription factors for stress-related genes, which may underlie the development of pathological anxiety.[12]

Behavioral scientists have contributed significantly to uncovering the psychological mechanisms contributing to anxiety. Conditioned responses of learned fear are more significant among anxiety-disordered individuals compared to controls, with an explanation of 2 likely mechanisms: first, there is greater excitatory conditioning to danger cues, and second, there is impaired inhibitory conditioning to safety signals.[13] 

Parenting behaviors implicate cross-generational influences on the development of childhood anxiety. These parenting behavioral systems include vicarious learning, social referencing, and modeling of parental anxiety. Furthermore, overly protective and overly critical parenting styles, parental response to child anxiety, and family accommodation of a child's anxiety all contribute to the conditioning and development of childhood anxiety.[14] Children of parents with depression and anxiety disorders are at a higher risk of developing a depressive or anxiety disorder.[15] Another mechanism for developing a specific phobia is through modeling, in which a person observes a reaction in another person and internalizes that other person's fears or warnings about the dangers of a specific object or situation.[16]


Anxiety disorders are among the most common mental health disorders, with an estimated prevalence of 5% to 34% worldwide, affecting both children and adults.[17][18][19] Lifetime 12-month prevalence estimates for specific phobia range from 7.7% to 12.5%; these estimates are maintained through different surveyed populations around the world.[20][21][22][23][24][25] The incidence rates for specific phobia are estimated to be 26.9% for individuals between 20 and 50 years.[25][26] Prevalence rates are higher in females compared to males,[27] and they decrease with age.[28][29] Sequentially, the most frequent types of specific phobias are those with stimuli related to animals, the natural environment, and then blood-injection-injury–related stimuli.[30]


Neuroanatomically, the amygdala is classically associated with provoking a fear response when stimulated. The amygdala and other fear-related neurocircuitry may share a similar neuroanatomy to anxiety neurocircuitry.[31] The amygdala and its connections to the frontal cortex (perirhinal cortex, ventrolateral prefrontal cortex, anterior insula) have received the most attention.[32] As the amygdala is part of the limbic system, other limbic system structures likely contribute to the development of anxiety, with a specific interest in the hippocampus, as it plays an integral role in fear learning and extinction.[33] Functional magnetic resonance imaging (fMRI) studies have found that hypofunction of the prefrontal cortex and anterior cingulate cortex is associated with emotional dysregulation and cognitive dysfunction in those with anxiety.[34]

The activation of fear neurocircuitry, with presumed anxiety neurocircuitry overlap, involves the release of various neurochemicals that lead to sympathetic stimulation. Classically characterized as a "fight-or-flight" reaction, this sympathetic response evolved to be adaptive and for a prompt behavioral response to avoid actual or perceived danger.[1] However, this response can be conditioned to over-activate, leading to pathological anxiety even when exposure to threat is low or should be low.[13] The neurochemicals involved in producing a fight-or-flight response are numerous and include norepinephrine, epinephrine, cortisol, neurosteroids, and vasopressin.[35] Dopamine likely has a modulatory role in producing anxiety-like behavior.[36] Low activity of postsynaptic serotonin 5-HT1A receptors contributes to pathological anxiety, which has led to the development of pharmacotherapy attempting to modulate these receptors to reduce anxiety.[37]

History and Physical

The presentation of specific phobia is variable. The chief complaint may be related to anxiety or impaired functioning in their social responsibilities due to symptoms of their illness. The chief complaint will likely be related to significant fear or anxiety in the presence of a specific situation or object, known as the phobic stimulus. It is essential to investigate if there is a single phobic stimulus or multiple. The anxiety reaction to the phobic stimulus must be greater than the expected reaction for the general population. In presence of the phobic stimuli, the anxiety must be severe, and it can produce panic attacks in certain cases. Anticipation of exposure to the phobic stimuli may also induce anxiety. The anxiety reaction is anticipated to evoke nearly every time there is exposure to the phobic stimulus. Children may express fear or anxiety by crying, tantrums, freezing, or clinging.

In specific phobia, the indivudal actively avoids the phobic stimulus, and this is termed active avoidance. Examples of active avoidance include taking a longer driving route to avoid a bridge, avoiding grass and gardens due to concern for spiders or insects, and refusing to visit a doctor due to fear of needles or medical procedures. Some active avoidance may be obvious, but certain behaviors are subtle, such as refusing to look at certain movies or books that may potentially have a phobic stimulus. Active avoidance may impact regular functioning, including social relationships and occupational responsibilities. 

The mental status examination is completed in psychiatric evaluations and has a variable presentation in specific phobia; however, the following areas should be carefully considered:

  • Behavior: When discussing the phobic stimulus, does the patient have anxious behaviors, such as constant movement, shaking, and small tremors? 
  • Speech: Is the patient's tone frightened when speaking about the phobic stimulus? Does the patient actively try and change the conversation away from the topic of the phobic stimulus?
  • Affect: Is the patient always anxious or only in the context of the phobic stimulus?
  • Thought process: Is the patient's thought process logical when thinking and discussing the phobic stimulus?  
  • Insight: What is the patient's understanding of their exaggerated response to the phobic stimulus?


Individuals with suspected specific phobia should be referred for a psychiatric evaluation.[38] The initial goals are to develop rapport with the patient, obtain historical information in detail from the patient, and conduct a mental status examination. Evaluation for applicable DSM-5-TR diagnostic criteria should be performed to make a formal diagnosis. 

DSM-5-TR Criteria for Specific Phobia

  1. Marked fear or anxiety about a specific object or situation (flying, heights, animals, seeing blood, or other). In children the fear or anxiety may be expressed by crying, tantrums, freezing, or clinging.
  2. The phobic object or situation almost always provokes immediate fear or anxiety.
  3. The phobic object or situation is actively avoided or endured with intense fear or anxiety.
  4. The fear or anxiety is out of proportion to the actual danger posed by the specific object or situation and to the sociocultural context.
  5. The fear, anxiety, or avoidance is persistent, typically lasting for 6 months or more.
  6. The fear, anxiety, or avoidance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.
  7. The disturbances are not better explained by the symptoms of another mental disorder, including fear, anxiety, and avoidance of situations associated with panic-like symptoms; objects or situations related to obsessions; reminders of traumatic events; separation anxiety; or social situations

Specify if:

  1. Animal (spiders, insects, dogs, etc)
  2. Natural environment (heights, storms, water, etc)
  3. Blood-injection-injury (needles, invasive medical procedures)
  4. Situational (airplanes, elevators, enclosed places)
  5. Other (situations that may lead to choking or vomiting, loud sounds, costumed characters)

Screening Tools

Multiple screening tools for anxiety disorders exist and have wide availability and validation. Generalized anxiety disorder screeners are common and widely available for adult screening, however most broader anxiety disorder screeners were designed to screen for anxiety disorders in children. When there is difficulty in obtaining the full diagnostic criteria from the interview alone, implementing a validated screening tool can be helpful in the diagnosis of specific phobia and in identifying possible comorbid conditions. 

Screen for Child Anxiety–Related Emotional Disorders 

Screen for Child Anxiety–Related Emotional Disorders (SCARED) is one of the most commonly used assessment tools for diagnosing anxiety disorders in children. SCARED is a child and parent self-report measure evaluated in numerous settings worldwide.[39] Various versions and revisions of the questionnaire have been developed. The most commonly used version consists of 41 questions. The total score is based on 5 subscale scores for the most common pediatric anxiety disorders:

  1. Generalized anxiety disorder
  2. Social phobia
  3. Social anxiety disorder (SAD)
  4. Somatic symptoms or panic disorder
  5. School phobia.

Each response is scored between 0 and 2, with a total score of 25 or higher having high sensitivity and specificity for discriminating between anxiety and nonanxiety disorders.[39] A 55% or higher reduction in the total score with treatment best predicts treatment response and a 60% or higher reduction in parent SCARED scores predicts remission.[39] There is a modified version of SCARED, the Screen for Adult Anxiety Related Disorders (SCAARED), available to screen adults for similar anxiety disorders as children. 

The SCARED assessment tool can be used free of charge with an acceptable time burden on clinicians and families, making it an excellent tool for diagnosing and managing anxiety disorders in children. SCARED cutoffs can also be used to guide treatment. For example, an insufficient reduction in the SCARED score after an adequate trial of behavioral therapy may indicate the need for pharmacotherapy.[39] Studies have shown some discordance in the information provided by the child and parent on this questionnaire without apparent contributory factors.[38] More research is warranted to understand the cause of "low informant agreement" and what factors contribute to this discrepancy. Still, the SCARED assessment tool is considered a stable, reliable, valid, and sensitive measure of anxiety, despite the informant discrepancy, which interestingly also stays stable over time. The SCARED screening tool has shown strict measurement invariance and solid test-retest reliability.

Youth Anxiety Measure

Youth Anxiety Measure (YAM) is a new parent-child questionnaire developed to assess anxiety disorder symptoms in children and adolescents according to the DSM-5. The scale consists of 2 parts: part I consists of 28 items and measures the major anxiety disorders; part II contains 22 items relating to specific phobias and agoraphobia.[40] The validation study for this questionnaire reports acceptable "face validity" with items successfully linked to the intended anxiety disorders and phobias. The authors report good internal consistency and reliability of the new measure with the parent-child agreement and concurrent, convergent, divergent, and discriminant validity.[40] An analysis of the psychometric qualities of the scale with the collection of normative data in nonclinical and clinical populations is still needed.

Anxiety Disorder Interview Schedule 

Anxiety Disorder Interview Schedule (ADIS) is a well-validated diagnostic interview suitable for measuring all anxiety disorders, mood disorders, and attention-deficit or attention-deficit hyperactivity disorder in children. The ADIS is a semistructured diagnostic interview that primarily assesses child anxiety disorders, and the diagnoses are derived from interviews with both the child and the parent.[41] The interviews cover the entire range of anxiety-related disorders outlined by the DSM-5. Each diagnosis is assigned a clinician severity rating (CSR), a symptoms severity rating, and a functional impairment rating.

A CSR of 4 or higher is required to provide a particular diagnosis. If the child and parent interviews yield different diagnoses and CSRs, the interviewer makes a composite diagnosis using recommended guidelines in the clinician manual. The ADIS's parent and child versions possess high inter-rater and test-retest reliability. One study reported almost perfect agreement on both the child and parent interview for diagnosing an anxiety disorder using ADIS. They also report almost perfect agreement regarding the severity of the primary diagnosis.[40] The ADIS is considered the gold-standard diagnostic evaluation for anxiety disorders. 

Pediatric Anxiety Rating Scale 

Pediatric Anxiety Rating Scale (PARS) is a clinician-rated scale of anxiety severity using the frequency of distress symptoms, avoidance behaviors, and interference in daily functioning.[40] In a multisite study evaluating 128 children aged 6 to 17, PARS was shown to have high inter-rater reliability, adequate test-retest reliability, and fair internal consistency. PARS scores are sensitive to treatment and parallel change in other measures of anxiety symptoms. This assessment tool has been validated in various populations and is frequently used worldwide in clinical and research settings.[42]

Treatment / Management

The optimal treatment strategy for specific phobia is cognitive behavioral therapy. However, cognitive behavioral therapy can be a challenging treatment modality for some patients to tolerate. Therefore, it is important to consider, if treatment is indicated in each individual case of specific phobia. Assessment of the impact that specific phobia has on quality of life, levels of distress, and social and occupational functioning, can help determine the individualized level of necessity to intervene or not.[9] Medication interventions can be considered alternative treatments for specific phobia; however, no medications have been cleared by the FDA for this purpose. 

Cognitive behavioral therapy in specific phobia is generally limited to exposure therapy, which can be emotionally taxing and challenging for patients to complete a full course of treatment. Exposure therapy implements the principles of operant conditioning and extinction learning via systematic desensitization and flooding. In methodical desensitization, the patient is exposed to a list of stimuli ranking from the least to the most anxiety-provoking. With this method, patients are taught various techniques to deal with anxiety, such as relaxation, breathing control, and alternative cognitive approaches.

The cognitive-behavioral approach includes reinforcing the realization that the phobic stimulus is safe. As the patient masters these techniques, they are taught to use them in the face of anxiety-provoking stimuli and induce relaxation. As the patients become desensitized to each stimulus on the scale, they keep moving up until the most anxiety-provoking stimuli no longer elicit any fear or anxiety.[43][44] 

Flooding, also known as implosion, is another behavioral technique that can be used to treat specific phobias. This technique involves increasing exposure to the stimulus to induce habituation and decrease anxiety. To be successful, behavioral therapy requires that the patient be committed to the treatment, there are distinctly identified problems and objectives, and there are alternative strategies for dealing with the patient’s feelings.[9]

Patients with a blood-injection-injury phobia are advised to tense their bodies and remain seated during the exposure to avoid the possibility of fainting from a vasovagal reaction. Also, beta-blockers and benzodiazepines can be used in patients when the phobia is associated with panic attacks.[9]

Other forms of treatment that may also be considered include virtual therapy, in which the patient is exposed to or interacts with the phobic stimulus on a computer screen. This field of treatment is relatively novel and requires more research. Other treatment modalities include hypnosis, supportive therapy, and family therapy. The goal of all forms of therapy is to help the patient recognize that the feared stimulus is not dangerous and to provide emotional support.[45][46]

Differential Diagnosis

Differential diagnoses for specific phobia include:


Specific phobia may resemble agoraphobia. However, in specific phobia, the phobic stimulus is specific to a particular situation rather than a general fear of difficulty escaping. 

Panic Disorder

Panic attacks can occur in specific phobia. Panic disorder is another anxiety disorder, in which panic attacks occur uncued or unexpected. This is in contrast to specific phobia, when panic attacks can occur after exposure to the phobic stimulus. 

Social Anxiety Disorder

Social anxiety disorder describes a general fear of being publicly scrutinized, embarrassed, or judged negatively by others in a variety of contexts. 

Posttraumatic Stress Disorder 

Avoidance is a key feature of Posttraumatic Stress Disorder (PTSD). However, in PTSD, the avoidance is related to situations associated with the trauma. To distinguish these disorders, the panel of symptoms needs to be taken into consideration. PTSD is expected to have persisting affective symptoms, while specific phobia (outside of the phobic stimulus) is not. 

Separation Anxiety Disorder

Separation anxiety is primarily a disorder of childhood, however, it can occur in adults as well. Separation anxiety disorder describes the fear of being separated from an attachment figure, while specific phobia results in anxiety when exposed to a phobic stimulus.  


Patients who are able to complete a course of cognitive behavioral therapy (exposure therapy) have a promising prognosis, but it is improved when there is maintenance therapy to ensure remission of symptoms.[9] Treatment response with benzodiazepines has been more limited to the duration treated with medication, and the treatment gains do not persist after discontinuation of the medication.[9] For those with limited response or difficulty tolerating cognitive behavioral therapy, utilizing a step-wise approach of pharmacotherapy to control severe anxiety and then proceeding to cognitive behavioral therapy may be appropriate. 


Uncontrolled specific phobia increases the risk of other comorbid psychiatric illnesses, specifically depression. Specific phobias can have significant impairment to social and occupational functioning, which can worsen psychological stress. Anxiety disorders are a risk factor for suicidality, even after controlling for co-occurring mental health disorders and life stress.[47] Estimates of population-attributable risk suggested a 7% to 10% risk of suicidality in adolescent patients with anxiety disorders.[47]

Deterrence and Patient Education

Exposure therapy is known to be a helpful treatment intervention for specific phobia; however, it is challenging for patients to endure and requires creative approaches to navigate a successful treatment course. For individuals with severe anxiety related to specific phobia, it may be optimal to initiate psychopharmacology treatment to treat symptoms prior to initiating exposure therapy. The goal of psychopharmacological intervention is to facilitate the patient's capacity to proceed with a course of exposure therapy. During a course of exposure therapy, the appropriate degree of thought process remodeling and encouragement is needed in order to keep patients motivated to continue through the treatment course.[9][48]

Enhancing Healthcare Team Outcomes

The diagnosis and management of specific phobia require the efforts of a coordinated interprofessional healthcare team. Both pediatric and adult providers are likely to encounter patients suffering from specific phobia. Multiple studies show that patients with anxiety disorders tend to have more frequent medical visits and increased healthcare utilization rates, especially for comorbid medical conditions or somatic complaints. Individuals with suspected specific phobia should be promptly referred for a behavioral health evaluation by a psychiatrist.

Barriers to appropriate diagnosis and treatment of patients with specific phobia include time constraints, unfamiliarity with diagnosing and managing anxiety disorders, concerns of stigmatizing patients, and reluctance to speak with parents or adult patients about mental illness. To overcome these barriers, there have been increased efforts in developing collaborative care models for training clinicians to identify and refer patients with anxiety disorders to psychiatric professionals in-clinic or by telehealth.[49] 

Once the diagnosis is made, patients may require intensive psychotherapy and psychoeducation to benefit from the treatment plan and understand expected outcomes. The clinical nurse plays a crucial role in educating parents and caregivers, reinforcing the techniques learned in therapy so they may be practiced at home. When pharmacotherapy is initiated, the clinical pharmacist assists in monitoring for adverse effects of the medications prescribed, performing medication reconciliation, and offering patient medication counseling. A collaborative interprofessional team of clinicians, behavioral therapists, nurses, and pharmacists can optimize clinical outcomes for specific phobia and help decrease the global burden of this disease. 



Sara Abdijadid


3/1/2024 1:48:10 AM



Bateson M, Brilot B, Nettle D. Anxiety: an evolutionary approach. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2011 Dec:56(12):707-15     [PubMed PMID: 22152639]


Weisberg RB. Overview of generalized anxiety disorder: epidemiology, presentation, and course. The Journal of clinical psychiatry. 2009:70 Suppl 2():4-9     [PubMed PMID: 19371500]

Level 3 (low-level) evidence


Walter HJ, Bukstein OG, Abright AR, Keable H, Ramtekkar U, Ripperger-Suhler J, Rockhill C. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 2020 Oct:59(10):1107-1124. doi: 10.1016/j.jaac.2020.05.005. Epub 2020 May 18     [PubMed PMID: 32439401]

Level 1 (high-level) evidence


Bittner A, Egger HL, Erkanli A, Jane Costello E, Foley DL, Angold A. What do childhood anxiety disorders predict? Journal of child psychology and psychiatry, and allied disciplines. 2007 Dec:48(12):1174-83     [PubMed PMID: 18093022]


Ezpeleta L, Keeler G, Erkanli A, Costello EJ, Angold A. Epidemiology of psychiatric disability in childhood and adolescence. Journal of child psychology and psychiatry, and allied disciplines. 2001 Oct:42(7):901-14     [PubMed PMID: 11693585]


Olatunji BO, Cisler JM, Tolin DF. Quality of life in the anxiety disorders: a meta-analytic review. Clinical psychology review. 2007 Jun:27(5):572-81     [PubMed PMID: 17343963]

Level 2 (mid-level) evidence


Garcia R, Neurobiology of fear and specific phobias. Learning     [PubMed PMID: 28814472]


Compton A. The psychoanalytic view of phobias. Part I: Freud's theories of phobias and anxiety. The Psychoanalytic quarterly. 1992 Apr:61(2):206-29     [PubMed PMID: 1594716]


Thng CEW, Lim-Ashworth NSJ, Poh BZQ, Lim CG. Recent developments in the intervention of specific phobia among adults: a rapid review. F1000Research. 2020:9():. pii: F1000 Faculty Rev-195. doi: 10.12688/f1000research.20082.1. Epub 2020 Mar 19     [PubMed PMID: 32226611]


Patel AK, Bryant B. Separation Anxiety Disorder. JAMA. 2021 Nov 9:326(18):1880. doi: 10.1001/jama.2021.17269. Epub     [PubMed PMID: 34751707]


Bögels SM, Knappe S, Clark LA. Adult separation anxiety disorder in DSM-5. Clinical psychology review. 2013 Jul:33(5):663-74. doi: 10.1016/j.cpr.2013.03.006. Epub 2013 Apr 2     [PubMed PMID: 23673209]


Battaglia M. Separation anxiety: at the neurobiological crossroads of adaptation and illness. Dialogues in clinical neuroscience. 2015 Sep:17(3):277-85     [PubMed PMID: 26487808]


Brew BK, Lundholm C, Gong T, Larsson H, Almqvist C. The familial aggregation of atopic diseases and depression or anxiety in children. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2018 Jun:48(6):703-711. doi: 10.1111/cea.13127. Epub 2018 Apr 1     [PubMed PMID: 29513367]


Lissek S, Powers AS, McClure EB, Phelps EA, Woldehawariat G, Grillon C, Pine DS. Classical fear conditioning in the anxiety disorders: a meta-analysis. Behaviour research and therapy. 2005 Nov:43(11):1391-424     [PubMed PMID: 15885654]

Level 1 (high-level) evidence


Lebowitz ER, Leckman JF, Silverman WK, Feldman R. Cross-generational influences on childhood anxiety disorders: pathways and mechanisms. Journal of neural transmission (Vienna, Austria : 1996). 2016 Sep:123(9):1053-67. doi: 10.1007/s00702-016-1565-y. Epub 2016 May 4     [PubMed PMID: 27145763]


Campos D, Bretón-López J, Botella C, Mira A, Castilla D, Mor S, Baños R, Quero S. Efficacy of an internet-based exposure treatment for flying phobia (NO-FEAR Airlines) with and without therapist guidance: a randomized controlled trial. BMC psychiatry. 2019 Mar 6:19(1):86. doi: 10.1186/s12888-019-2060-4. Epub 2019 Mar 6     [PubMed PMID: 30841930]

Level 1 (high-level) evidence


Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H -U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. International journal of methods in psychiatric research. 2012 Sep:21(3):169-84. doi: 10.1002/mpr.1359. Epub 2012 Aug 1     [PubMed PMID: 22865617]


Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues in clinical neuroscience. 2015 Sep:17(3):327-35     [PubMed PMID: 26487813]


Ehrenreich JT, Santucci LC, Weiner CL. SEPARATION ANXIETY DISORDER IN YOUTH: PHENOMENOLOGY, ASSESSMENT, AND TREATMENT. Psicologia conductual. 2008 Jan 1:16(3):389-412     [PubMed PMID: 19966943]


Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of general psychiatry. 1994 Jan:51(1):8-19     [PubMed PMID: 8279933]

Level 3 (low-level) evidence


Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of general psychiatry. 2005 Jun:62(6):593-602     [PubMed PMID: 15939837]

Level 3 (low-level) evidence


Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Social psychiatry and psychiatric epidemiology. 1998 Dec:33(12):587-95     [PubMed PMID: 9857791]

Level 3 (low-level) evidence


de Graaf R, ten Have M, van Gool C, van Dorsselaer S. Prevalence of mental disorders and trends from 1996 to 2009. Results from the Netherlands Mental Health Survey and Incidence Study-2. Social psychiatry and psychiatric epidemiology. 2012 Feb:47(2):203-13. doi: 10.1007/s00127-010-0334-8. Epub 2011 Jan 1     [PubMed PMID: 21197531]

Level 3 (low-level) evidence


Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V, Lépine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J, Arbabzadeh-Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M, Domingo-Salvany A, Ferrer M, Joo SS, Martínez-Alonso M, Matschinger H, Mazzi F, Morgan Z, Morosini P, Palacín C, Romera B, Taub N, Vollebergh WA, ESEMeD/MHEDEA 2000 Investigators, European Study of the Epidemiology of Mental Disorders (ESEMeD) Project. 12-Month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta psychiatrica Scandinavica. Supplementum. 2004:(420):28-37     [PubMed PMID: 15128385]


Wardenaar KJ, Lim CCW, Al-Hamzawi AO, Alonso J, Andrade LH, Benjet C, Bunting B, de Girolamo G, Demyttenaere K, Florescu SE, Gureje O, Hisateru T, Hu C, Huang Y, Karam E, Kiejna A, Lepine JP, Navarro-Mateu F, Oakley Browne M, Piazza M, Posada-Villa J, Ten Have ML, Torres Y, Xavier M, Zarkov Z, Kessler RC, Scott KM, de Jonge P. The cross-national epidemiology of specific phobia in the World Mental Health Surveys. Psychological medicine. 2017 Jul:47(10):1744-1760. doi: 10.1017/S0033291717000174. Epub 2017 Feb 22     [PubMed PMID: 28222820]

Level 3 (low-level) evidence


Bijl RV, De Graaf R, Ravelli A, Smit F, Vollebergh WA, Netherlands Mental Health Survey and Incidence Study. Gender and age-specific first incidence of DSM-III-R psychiatric disorders in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Social psychiatry and psychiatric epidemiology. 2002 Aug:37(8):372-9     [PubMed PMID: 12195544]

Level 3 (low-level) evidence


Angst J, Paksarian D, Cui L, Merikangas KR, Hengartner MP, Ajdacic-Gross V, Rössler W. The epidemiology of common mental disorders from age 20 to 50: results from the prospective Zurich cohort Study. Epidemiology and psychiatric sciences. 2016 Feb:25(1):24-32. doi: 10.1017/S204579601500027X. Epub 2015 Mar 24     [PubMed PMID: 25802979]


Stinson FS, Dawson DA, Patricia Chou S, Smith S, Goldstein RB, June Ruan W, Grant BF. The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychological medicine. 2007 Jul:37(7):1047-59     [PubMed PMID: 17335637]

Level 3 (low-level) evidence


Sigström R, Skoog I, Karlsson B, Nilsson J, Östling S. NINE-YEAR FOLLOW-UP OF SPECIFIC PHOBIA IN A POPULATION SAMPLE OF OLDER PEOPLE. Depression and anxiety. 2016 Apr:33(4):339-46. doi: 10.1002/da.22459. Epub 2015 Dec 8     [PubMed PMID: 26645153]


Ausín B, Muñoz M, Castellanos MÁ, García S. Prevalence and Characterization of Specific Phobia Disorder in People over 65 Years Old in a Madrid Community Sample (Spain) and its Relationship to Quality of Life. International journal of environmental research and public health. 2020 Mar 15:17(6):. doi: 10.3390/ijerph17061915. Epub 2020 Mar 15     [PubMed PMID: 32183487]

Level 2 (mid-level) evidence


Mochcovitch MD, da Rocha Freire RC, Garcia RF, Nardi AE. A systematic review of fMRI studies in generalized anxiety disorder: evaluating its neural and cognitive basis. Journal of affective disorders. 2014:167():336-42. doi: 10.1016/j.jad.2014.06.041. Epub 2014 Jul 2     [PubMed PMID: 25020268]

Level 1 (high-level) evidence


Chu B, Marwaha K, Sanvictores T, Ayers D. Physiology, Stress Reaction. StatPearls. 2024 Jan:():     [PubMed PMID: 31082164]


Zarrindast MR, Khakpai F. The Modulatory Role of Dopamine in Anxiety-like Behavior. Archives of Iranian medicine. 2015 Sep:18(9):591-603     [PubMed PMID: 26317601]


Gordon JA, Hen R. The serotonergic system and anxiety. Neuromolecular medicine. 2004:5(1):27-40     [PubMed PMID: 15001810]


Vaughan J, Coddington JA, Ahmed AH, Ertel M. Separation Anxiety Disorder in School-Age Children: What Health Care Providers Should Know. Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners. 2017 Jul-Aug:31(4):433-440. doi: 10.1016/j.pedhc.2016.11.003. Epub 2016 Dec 21     [PubMed PMID: 28012800]


Masi G, Mucci M, Millepiedi S. Separation anxiety disorder in children and adolescents: epidemiology, diagnosis and management. CNS drugs. 2001:15(2):93-104     [PubMed PMID: 11460893]


Karaytuğ MO, Tamam L, Demirkol ME, Namlı Z, Gürbüz M, Yeşiloğlu C. Impact of Childhood Trauma and Adult Separation Anxiety Disorder on Quality of Life in Individuals with Schizophrenia. Neuropsychiatric disease and treatment. 2023:19():181-196. doi: 10.2147/NDT.S391897. Epub 2023 Jan 23     [PubMed PMID: 36714165]

Level 2 (mid-level) evidence


Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, Ginsburg GS, Rynn MA, McCracken J, Waslick B, Iyengar S, March JS, Kendall PC. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. The New England journal of medicine. 2008 Dec 25:359(26):2753-66. doi: 10.1056/NEJMoa0804633. Epub 2008 Oct 30     [PubMed PMID: 18974308]


McCormack CC, Mennies RJ, Silk JS, Stone LB. How anxious is too anxious? State and trait physiological arousal predict anxious youth's treatment response to brief cognitive behavioral therapy. BMC psychology. 2020 May 12:8(1):48. doi: 10.1186/s40359-020-00415-3. Epub 2020 May 12     [PubMed PMID: 32398128]


Gibby BA, Casline EP, Ginsburg GS. Long-Term Outcomes of Youth Treated for an Anxiety Disorder: A Critical Review. Clinical child and family psychology review. 2017 Jun:20(2):201-225. doi: 10.1007/s10567-017-0222-9. Epub     [PubMed PMID: 28181040]


Voltas N, Hernández-Martínez C, Arija V, Canals J. The natural course of anxiety symptoms in early adolescence: factors related to persistence. Anxiety, stress, and coping. 2017 Nov:30(6):671-686. doi: 10.1080/10615806.2017.1347642. Epub 2017 Jul 5     [PubMed PMID: 28678525]


Ginsburg GS, Becker-Haimes EM, Keeton C, Kendall PC, Iyengar S, Sakolsky D, Albano AM, Peris T, Compton SN, Piacentini J. Results From the Child/Adolescent Anxiety Multimodal Extended Long-Term Study (CAMELS): Primary Anxiety Outcomes. Journal of the American Academy of Child and Adolescent Psychiatry. 2018 Jul:57(7):471-480. doi: 10.1016/j.jaac.2018.03.017. Epub 2018 May 9     [PubMed PMID: 29960692]


Spurling KJ, McGoldrick VP. Blood-Injection-Injury (B-I-I) Specific Phobia Affects the Outcome of Hypoxic Challenge Testing. Aerospace medicine and human performance. 2017 May 1:88(5):503-506. doi: 10.3357/AMHP.4730.2017. Epub     [PubMed PMID: 28417842]


Kogan CS, Stein DJ, Maj M, First MB, Emmelkamp PM, Reed GM. The Classification of Anxiety and Fear-Related Disorders in the ICD-11. Depression and anxiety. 2016 Dec:33(12):1141-1154. doi: 10.1002/da.22530. Epub 2016 Jul 13     [PubMed PMID: 27411108]


Zwanzger P. [Pharmacotherapy of Anxiety Disorders]. Fortschritte der Neurologie-Psychiatrie. 2016 May:84(5):306-14. doi: 10.1055/s-0042-106764. Epub 2016 Jun 14     [PubMed PMID: 27299791]


Ori R, Amos T, Bergman H, Soares-Weiser K, Ipser JC, Stein DJ. Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders. The Cochrane database of systematic reviews. 2015 May 10:2015(5):CD007803. doi: 10.1002/14651858.CD007803.pub2. Epub 2015 May 10     [PubMed PMID: 25957940]

Level 1 (high-level) evidence


Boden JM, Fergusson DM, Horwood LJ. Anxiety disorders and suicidal behaviours in adolescence and young adulthood: findings from a longitudinal study. Psychological medicine. 2007 Mar:37(3):431-40     [PubMed PMID: 17109776]


Becker-Haimes EM, Stewart RE, Frank HE. It's all in the name: why exposure therapy could benefit from a new one. Current psychology (New Brunswick, N.J.). 2022 Jun 2:():1-7. doi: 10.1007/s12144-022-03286-6. Epub 2022 Jun 2     [PubMed PMID: 35669210]


Ramsawh HJ, Chavira DA, Stein MB. Burden of anxiety disorders in pediatric medical settings: prevalence, phenomenology, and a research agenda. Archives of pediatrics & adolescent medicine. 2010 Oct:164(10):965-72. doi: 10.1001/archpediatrics.2010.170. Epub     [PubMed PMID: 20921356]